Torrent Pharmaceuticals Limited — Board Meeting, 25-10-2024: Outcome of Board Meeting

Torrent Pharmaceuticals reported Q2 FY25 results, with revenues at ₹2,889 crores, up 9% YoY. Operating EBITDA rose 14% to ₹939 crores, while net profit after tax increased by 17% to ₹453 crores. The company's India revenues grew 13%, driven by strong performances in chronic therapies. Challenges in insulin revenue were noted due to maintenance activities, expected to recover in Q4. Adjusted growth metrics reflect a healthy operational trajectory with a strong focus on ongoing R&D.